Karnataka gets four of the six genome sequencing labs approved by DBT

The Department of Biotechnology (DBT) has approved the inclusion of six private genomic sequencing labs into the Indian SARS-CoV-2 Genomics Consortium (INSACOG). The network of labs is identified by the government to sequence the coronavirus disease (Covid) samples. Four of these labs are from Karnataka. The labs from Karnataka are Strand Life Sciences, Genotypic Technologies, Medgenome and Eurofins Genomics India, according to an official memorandum from the ministry of science and technology. The communication from the Union government also stated that the inclusion of the 6 labs is subject to certain conditions like the sequencing charges are to be borne by the private labs and not passed on to the patients. Further, the labs would be required to indicate the source of funding in order to undertake sequencing activities. The sequencing information will be confidential and would not be shared to any third party source or public. The private labs will need to preserve the RNA samples for a specific period, among other terms and conditions to ensure the quality of sequencing. In December 2021, the Karnataka government to expedite diagnosis of the Omicron variant of SARS-CoV-2 virus set up additional genomic sequencing labs. This was in addition to the National Institute of Mental Health and Neuro Sciences (NIMHANS) and the National Centre for Biological Sciences (NCBS). During the second wave of Covid-19, the state government had said six genome sequencing labs were being set up at Bengaluru, Mysuru, Shivamogga, Hubballi, Mangaluru and Vijayapura. These labs are expected to strengthen the diagnostic infrastructure in the state. This is because early detection is the key to faster isolation and treatment access, said Karnataka Chief Minister Basavaraj Bommai. In the wake of the Omicron variant spread, the state took up measures to set up more genomic sequencing labs. Right now all of Karnataka

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!